NEW ACTION ALERT: Hagens Berman Alerts Embraer S.A. (NYSE:

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NEW ACTION ALERT: Hagens Berman Alerts Embraer S.A. (NYSE: ERJ) Investors to Securities Class Action and the October 7, 2016 Lead Plaintiff Deadline

SAN FRANCISCO, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in Embraer S.A. (NYSE: ERJ ) to the pending securities class action filed in the United States District Court for the Southern District of New York and to the October 7, 2016 Lead Plaintiff Deadline.

If you purchased or otherwise acquired securities of Embraer S.A. between April 16, 2012 and July 28, 2016 and suffered over $75,000 in losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit

https://www.hbsslaw.com/cases/ERJ

or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing ERJ@hbsslaw.com .

This class action concerns Embraer’s alleged failure to disclose its illicit bribery scheme, during which the Company paid Dominican Republic officials to secure contracts for the sale of Embraer aircraft.

Since early 2010, the United States Securities and Exchange Commission (“SEC”) has been investigating Embraer for possible violations of the U.S. Foreign Corrupt Practices Act (“FCPA”). 

The SEC reportedly provided evidence from its investigation to Brazil’s law enforcement authorities, who filed criminal bribery charges against eight of Embraer’s former executives and directors and an Embraer sales consultant in September 2014. 

On March 16, 2016, after admitting to bribery, the criminally-charged sales consultant stated that the Company’s CEO (Federico Pinheiro Fleury Curado) and other top management knew of the illicit bribery scheme. 

The Company announced on June 9, 2016, that they would replace their CEO in July 2016.  On this news, the price of Embraer’s American Depository Receipts (ADRs) fell 5.44% to $20.51.

On July 29, 2016, Embraer abruptly reported a quarterly loss of $99.4 million, due in part to a $200 million loss contingency “reflecting the likely outcome” of its negotiations with U.S. officials conducting the bribery probe.  This news sent the price of Embraer ADRs down nearly 14% to close at $18.27.

Embraer and its executives allegedly knew and failed to disclose that (1) the Company undertook an illicit bribery scheme; (2) the CEO and top executives knew of the illicit scheme; (3) the consequences of the illicit scheme would cost the Company hundreds of millions of dollars; and, as a result, (4) the Company’s reported financials were false.

“Among other facts, we’re investigating when the $200 million contingency became probable and should have been reported,” said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding Embraer S.A. should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email ERJ@hbsslaw.com .

About Hagens Berman Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com . Read the Firm’s Securities Newsletter , and visit the blog . For the latest news visit our newsroom or follow us on Twitter at @classactionlaw .

Contact: Reed Kathrein, 510-725-3000

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 15

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 11

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 20

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 17

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 22

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 19

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 20

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 23

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 18

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights into Stella-Jones Conference Call for Q3 Results

Updated Category News Views 70

Upcoming Conference Call for Stella-Jones Inc. Stella-Jones Inc. (TSX: SJ), a prominent player in the manufacturing of pressure-treated wood products, is set to hold a significant conference call to discuss its third quarter results. Details of the Conference Call The conference call is open to investors, analysts, and all interested parties. It will take place on...

Continue Reading
Total Voting Rights Announcement for Northern Venture Trust

Updated Category News Views 75

Update on Total Voting Rights Northern Venture Trust PLC has released a key update concerning its total voting rights. In line with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, the Company is informing the market about its present capital structure. Overview of Ordinary Shares As per the latest information, Northern Venture Trust PLC's...

Continue Reading
Northrop Grumman Faces Investor Scrutiny Amid Financial Decline

Updated Category News Views 431

Investor Concerns Around Northrop Grumman Investors holding shares in Northrop Grumman Corporation (NYSE: NOC) are facing critical developments as they are encouraged to evaluate their positions in light of recent financial disclosures and ongoing investigations by legal entities. This alert revolves around Northrop Grumman's recent performance and future implications...

Continue Reading
Nature's Sunshine Welcomes Katie May to Board Leadership

Updated Category News Views 420

Nature's Sunshine Embraces New Leadership with Katie A. May Nature's Sunshine Products, Inc. is thrilled to announce that Katie A. May has joined its board of directors, marking a significant step in enhancing leadership and direction within the company. With a rich background in ecommerce and logistics, Katie's new role reflects the company's commitment to further...

Continue Reading
NewAmsterdam Pharma Announces Participation in Key Investor Conferences

Updated Category News Views 79

NewAmsterdam Pharma to Attend Investor Conferences NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is a leading biopharmaceutical firm committed to creating innovative oral medications designed to reduce low-density lipoprotein (LDL) cholesterol levels for individuals at risk of cardiovascular disease (CVD). The company is preparing for a series of upcoming investor...

Continue Reading